Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein
International Journal of Molecular Sciences · 02.08.2024 · 25 (15) · 8471
DOI: 10.3390/ijms25158471 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.08.2024. Verfasst von Ying-Tzu Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, China Medical University, No. 100, Section 1, Jingmao Road, Beitun District, Taichung 406040, Taiwan. Hauptthemen laut MEDLINE: Isoflavones, Drug Resistance, Neoplasm, Oxidative Stress, Molecular Docking Simulation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University, National Science and Technology Council.
Abstract (Originalsprache)
Multidrug resistance (MDR) remains the most difficult problem facing conventional chemotherapy for cancers. Astragalus membranaceus is a historically traditional Chinese medicine. One of its bioactive components, formononetin, exhibits antitumor effects on various cancers. However, the effects of formononetin on MDR cancers have not been evaluated. Therefore, we investigated the defense’s effects of formononetin on MDR. We used rhodamine 123 and doxorubicin efflux assays to analyze the inhibition kinetics of P-glycoprotein (P-gp) mediated-efflux. Cell viability was detected by sulforhodamine B assay, and the synergistic effects of formononetin combined with chemotherapeutic agents were further calculated using CompuSyn software. Molecular docking was performed with iGEMDOCK. We discovered that formononetin considerably induced oxidative stress and the disruption of mitochondrial membrane potential in MDR cancer cells. Furthermore, formononetin inhibits the P-gp efflux function by ATPase stimulation and the uncompetitive inhibition of P-gp-mediated effluxes of rhodamine 123 and doxorubicin. The molecular docking model indicates that formononetin may bind to P-gp by strong hydrogen bonds at Arginine (Arg) 489 and Glutamine (Gln) 912. Formononetin exhibits significant synergistic effects with vincristine and doxorubicin toward MDR cancer cells, and it synergistically suppressed tumor growth in vivo with paclitaxel. These results suggest that formononetin should be seen as a potential candidate for the adjuvant therapy of MDR cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, China Medical University, No. 100, Section 1, Jingmao Road, Beitun District, Taichung 406040, Taiwan.
- Department of Pharmacy, China Medical University Hospital, Taichung 404327, Taiwan.
- Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan.
ORCID-Profile: Chin-Chuan Hung
Förderung
- China Medical University
- National Science and Technology Council
Zitieren
APA
Chang, Y. T., Wu, I. T., Sheu, M. J., Lan, Y. H., & Hung, C. C. (2024). Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein. International Journal of Molecular Sciences, 25(15), 8471. https://doi.org/10.3390/ijms25158471
Vancouver
Chang YT, Wu IT, Sheu MJ, Lan YH, Hung CC. Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein. International Journal of Molecular Sciences. 2024;25(15):8471. doi:10.3390/ijms25158471
BibTeX
@article{Chang2024,
author = {Chang, Ying-Tzu and Wu, I-Ting and Sheu, Ming-Jyh and Lan, Yu-Hsuan and Hung, Chin-Chuan},
title = {Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {15},
pages = {8471},
doi = {10.3390/ijms25158471}
}
EUVIMED